IDEX: A $260 Target on a Run That's Already Been Priced

A price-target raise on IDEX (NYSE: IEX) sounds like fresh confirmation that the stock is going higher. What it actually is, this week, is a Wall Street firm marking a run that already happened. Oppenheimer lifted its target to $260 from $250 and kept an Outperform rating, on a stock that is up roughly 26% this year and ~39% over the trailing twelve months, sitting just below its 52-week high. A target is one analyst's opinion of fair value — a useful label, but not evidence of cheapness. The question worth asking is whether IDEX's shares have already been paid for the good news they keep delivering.

Behind the headline sits a genuinely improving company. On July 29, IDEX reported record orders of more than $1 billion, up 29%, alongside second-quarter sales up 6% and adjusted earnings per share of $2.32, up 12%. Management used the quarter to raise its full-year outlook for the third time running: organic sales growth of 5% to 6% and adjusted diluted EPS of $8.70 to $8.85. That is the real substance of the story a beginner would otherwise read as "Oppenheimer likes it."

The reason those orders matter more than the analyst's stamp is that they are the forward proof. A +29% jump in orders sitting against a conservative +5% to +6% organic sales guide says revenue has not yet caught up to demand; the order book is what becomes billed and shipped in the quarters ahead. IDEX is a collection of precision-engineered niche businesses — pumps and flow control, fire and rescue, and its Health & Science Technologies segment — run through an "80/20" model that concentrates resources on its best-selling, highest-margin lines. Strong orders plus that operating discipline is exactly the combination a numbers-first investor wants to see before believing a growth story, and the company has been compounding it: record orders appeared again in the first quarter, and Health & Science was singled out for momentum then too.

So the discouraging part is not the business. It is the price you must now pay to own it. At about $225 and a full-year 2026 adjusted-EPS midpoint of roughly $8.78, IDEX trades near 26 times this year's earnings, with earnings themselves expected to grow in the low-to-mid double digits. A multiple two and a half times the growth rate is a premium, not a bargain — especially against peers like Dover at about 15 times EBITDA and Pentair closer to 13 times. The market has not overlooked this recovery; it has already awarded it. The stock is up sharply over the past year precisely because everyone can now see the same order book and the same raised guidance.

That is the divergence worth being honest about. This investor's edge comes from buying where the math underprices the narrative — where forward earnings power is real but the multiple has not caught up. Here the narrative and the price have already reconciled. The strong orders justify a good company; they do not justify a full multiple on top of a full run. An analyst raising a target to $260 is doing arithmetic on a stock that has already re-rated, which makes the number a momentum marker rather than a hidden-value signal.

That does not make IDEX a sell — a durable, well-run compounder that keeps raising guidance is not a falling-knife chart, and its order momentum could easily push revenue above even the freshly raised guide. But for a reader deciding whether to chase, the honest answer is that the easy part of this story has been priced. An entry that makes sense would come from one of two things: a pullback that brings the multiple back in line with mid-single-digit organic growth, or order numbers that keep dropping into revenue faster than the market expects, lifting the forward earnings base under that 26x. Until one of those happens, the only case for buying is the momentum case — and momentum is not a valuation.